HbA1c is routinely used in the management of diabetes to monitor long term glycemic control and assess the risk of developing complications. It has also recently been recommended for use in the diagnosis of diabetes.
And while A1c is a commonly ordered test, A1c testing can be a tricky proposal, including the possibility that Hb variants and adducts may affect the accuracy of your HbA1c method. Each method must be evaluated for potential interference in the presence of the most common heterozygous variants and other known interferents.
This presentation will show labs how best to assess interferences, results from several interference studies, and general recommendations about interpretation of test results.
This program is designed for laboratory managers, supervisors, and directors; point-of-care coordinators and supervisors; and other healthcare professionals involved in performing or managing HbA1c testing.
Randie R. Little, PhD, Professor, Departments of Pathology & Anatomical Sciences and Child Health and Director, Diabetes Diagnostic Laboratory, University of Missouri (Columbia, MO)
Steven D. Wittlin, MD, Clinical Director, Endocrine-Metabolism Division and Director, Diabetes Service, University of Rochester Medical Center (Rochester, NY)